कृपया अन्य खोज का प्रयास करें
Philogen S.p.A., a biotechnology company, develops drugs for oncology and chronic inflammatory diseases. It is developing Nidlegy, a combination of the immunocytokines L19IL2 and L19TNF developed intralesional treatment for locoregional melanoma and non-melanoma skin cancers; Fibromun, a human immunomodulatory product consisting of L19 antibody and TNF to treat soft tissue sarcoma, leiomyosarcoma, and glioma; and Darleukin (L19IL2), a human immunostimulatory product consisting of the human L19 antibody fused to the human cytokine interleukin-2 (IL2), which is in phase II clinical trial for the treatment of non-small cell lung cancer. The company is also developing Dodekin, a human immunostimulatory product that comprises vascular targeting antibody fused to interleukin-12 that is in phase I/II clinical trial to treat advanced solid tumors; Dekavil (F8IL10), an anti-inflammatory product, which is in phase II clinical trial for the treatment of chronic inflammatory disorders; Onco IX (PHC-102), a 99mTc labelled small molecule radiotracer for the non-invasive detection of carbonic anhydrase IX (CAIX) expressed on the surface of solid tumors that is in phase 1 clinical trial; and OncoFAP, a small molecule radiotracer for the non-invasive detection of various metastatic solid tumors targeting fibroblast activation protein, which is in phase 1 clinical trial. In addition, it is developing Tripokin, a fully-human immunostimulatory product consisting of tumor necrosis factor and interleukin-2 fused into one molecular entity, which is in preclinical stage. Philogen S.p.A. was founded in 1996 and is based in Siena, Italy.
नाम | आयु | पहले | शीर्षक |
---|---|---|---|
Maria Angela Fantini | - | 2021 | Auditor |
Roberto Bonini | - | 2021 | Auditor |
Duccio Neri | - | 1996 | Co-Founder & Executive Chairman |
Stefano Mecacci | - | - | Chairman of Statutory Auditor |
Roberto Ferraresi | - | 2019 | Independent Director |
Sergio Gianfranco Luigi Maria Dompé | - | - | Director |
Guido Guidi | 68 | 2019 | Member of Scientific Advisory Board & Director |
Marta Bavasso | - | - | Lead Independent Director |
Cornelia Halin Winter | - | - | Member of Scientific Advisory Board |
Leopoldo Giampaolo Zambeletti | 54 | - | Director |
Wolfgang Berdel | - | - | Member of Scientific Advisory Board |
Nathalie Francesca Maria Dompé | 36 | - | Director |
Maria Giovanna Calloni | 58 | 2022 | Director |
Dario Neri | 60 | 1996 | Co-Founder, CEO , MD, CSO, President of the Scientific Advisory Board & Director |
Pierluigi Matteoni | - | - | Standing Auditor |
Alessandra Pinzuti | - | 2021 | Standing Auditor |
Giovanni Neri | - | - | Co-Founder, Head of IP & Licensing and Executive Director |
क्या आप सच में %USER_NAME% को ब्लॉक करना चाहते हैं?
ऐसा करके, आप और %USER_NAME% नहीं देख पाएंगे किसी अन्य के Investing.com की पोस्ट में से कोई भी।
%USER_NAME% को सफलतापूर्वक आपकी ब्लॉक सूची में जोड़ लिया गया है
क्योंकि आपने इस व्यक्ति को अनब्लॉक कर दिया है, आपको ब्लॉक को रिन्यू करने से पहले 48 घंटे प्रतीक्षा करनी होगी।
मुझे लगता है कि यह टिपण्णी:
धन्यवाद!
आपकी रिपोर्ट समीक्षा के लिए हमारे मॉडरेटर को भेजी गई है